Should I Buy DOX? DOX 2026 Analysis

Should You Buy Amdocs Ltd (DOX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

73.340

1 Day change

3.11%

52 Week Range

95.410

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price is in a confirmed downtrend (bearish MAs + worsening MACD), and near-term pattern stats skew slightly negative (next week bias).
Oversold RSI (very low) raises the odds of a short-term bounce, but the trend still favors downside until the stock reclaims key levels (at least above ~78 pivot).
Sentiment is mixed-to-negative: hedge funds have been aggressive sellers and Wall Street targets were cut post-earnings, despite the EPS beat.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.
Politicians/Congress: No recent congress trading data available (and no politician activity provided).

Technical Analysis

Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5 (rally attempts are likely to be sold).
Momentum: MACD histogram at -1.159 and negatively expanding = downside momentum is strengthening.
RSI: RSI_6 at 11.323 = deeply oversold (can trigger reflex bounces, but not a trend change by itself).
Levels: Current 72.58 is just below S1 (73.253) and above S2 (70.103). A clean break below ~70 raises downside risk; reclaiming the pivot ~78.353 would be the first meaningful repair signal.
Probabilistic near-term bias from similar patterns: ~20% chance to -0.96% next day, -3.62% next week, ~flat next month (+0.17%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Put/Call ratios are low (OI PCR 0.43; Volume PCR 0.36) = options positioning/flow leans bullish (call-heavy) despite the weak chart.
Implied volatility is elevated vs its own history: IV percentile 98.01 (options priced rich), while 30d IV (21.38) is below historical vol (30.35) suggesting recent realized moves have been larger than current implied.
Activity: Today’s volume 1,287 is ~117.75% of 30-day average; open interest 18,704 is ~107.6% of average = above-normal attention, but not extreme.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings beat: Q1 non-GAAP EPS 1.81 vs expectations (beat) with revenue 1.16B, +4.5% YoY.
- Potential relief bounce setup: extremely oversold RSI can spark a quick rebound if selling pressure eases.
- Options flow skewed bullish (call-heavy put/call ratios), which can support short-term upside attempts.

Neutral/Negative Catalysts

- Technical damage: bearish moving averages and deteriorating MACD indicate trend-following pressure remains.
- Leadership change: CEO retirement/transition introduces execution/continuity uncertainty near-term.
- Hedge fund behavior: “Hedge Funds are Selling” with selling up 1713.29% last quarter (strong negative positioning signal).
- Analyst sentiment drifted down post-earnings (targets cut; one downgrade), suggesting limited near-term catalysts in Street narrative.

Financial Performance

Latest quarter (per news, FY2026 Q1): Revenue 1.16B (+4.5% YoY) and non-GAAP EPS 1.81 (beat) = modest top-line growth with better-than-expected profitability.
Prior reported snapshot (2025/Q4): Revenue 1.150B (-8.99% YoY) but Net Income +11.50% YoY, EPS +15.79% YoY, and Gross Margin 36.17% (+7.65% YoY) = margins/profitability improved even while revenue contracted.
Overall: profitability trend looks better than revenue trend; growth visibility appears constrained based on guidance-related commentary in analyst notes.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: multiple price target cuts after the earnings report (Barclays 111→92; BofA 100→97; Stifel 100→97) and one downgrade (Wolfe to Peer Perform).
Current Street stance (pros): Barclays remains Overweight; BofA and Stifel remain Buy-rated—suggesting longer-term confidence in the franchise and earnings power.
Current Street stance (cons): Wolfe cites lack of catalysts and concerns around growth/margin assumptions in FY26 guidance; overall PT cuts imply reduced upside expectations near-term.

6 Analyst Rating

Wall Street analysts forecast DOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOX is 99 USD with a low forecast of 87 USD and a high forecast of 111 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 71.130

Low

Averages

High

111

Current: 71.130

Low

Averages

High

111

Barclays

Overweight -> NULL

downgrade

$111 -> $92

AI Analysis

2026-02-05

New

Reason

Barclays

Price Target

$111 -> $92

AI Analysis

2026-02-05

New

downgrade

Overweight -> NULL

Reason

Barclays lowered the firm's price target on Amdocs to $92 from $111 and keeps an Overweight rating on the shares. The views the company's results "resilient", with several wins in strategic domains. With the macro backdrop weighing on Amdocs' end markets, investors will focus on the company's double-digit earnings return policy, the analyst tells investors in a research note.

Stifel

Buy

downgrade

$97 -> $88

2026-02-04

New

Reason

Stifel

Price Target

$97 -> $88

2026-02-04

New

downgrade

Buy

Reason

Stifel lowered the firm's price target on Amdocs (DOX) to $88 from $97 and keeps a Buy rating on the shares following earnings. The "most notable item this quarter" was the T-Mobile (TMUS) contract renewal announcement with a five-year term given that the lack of renewal to-date was a key investor concern, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOX

Unlock Now

DOX Should I Buy

DOX Should I Buy

Should You Buy Amdocs Ltd (DOX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch